News

Researchers Recruiting Cushing’s Disease Patients for Osilodrostat Phase 3 Trial

A new Phase 3 clinical trial (NCT02697734) is actively recruiting Cushing’s disease patients in several countries to test the safety and effectiveness of the investigational therapy osilodrostat (LCI699). The 48-week, multicenter, randomized, double-blind, placebo-controlled study is sponsored by Novartis Pharmaceuticals. Estimated enrollment is 69 patients at 26 locations…

Cushing’s Related Tumors Require Lymph Vessel Growth for Steroid Production, Study Suggests

Aggressive adrenocortical carcinomas differ from tumors linked to Cushing’s syndrome in the density of blood and lymph vessels, according to a research team at Portugal’s University of Porto. Their study, “Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors,” appeared in the journal Pathology & Oncology Research. It offers insights into the…

UK’s National Health Service Approves Daxas as Treatment for COPD

The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…